Prediction of MRD in Leukemia Patients (SJ-14-0012)

St. Jude Reference #SJ-14-0012

Description

Researchers at St. Jude correlated NK cell genotype and phenotype at diagnosis with minimal residual disease (MRD) after induction chemotherapy in childhood acute lymphoblastic leukemia (ALL), with a specific aim of developing a novel NK model to predict treatment response.

This resulted in the discovery of NK cell biomarkers that can predict response to induction chemotherapy in pediatric ALL at diagnosis. Not all natural killer (NK) cells are equally cytotoxic against leukemia because of differences in receptor gene content and surface expression. A strong NK effector phenotype is associated with better leukemia control by analyzing the NK cells and leukemia blasts of 244 pediatric patients with ALL at diagnosis by killer-cell immunoglobulin-like receptor (KIR) typing and immunophenotyping. The results were correlated statistically to post-induction MRD status.


 

Keywords

MRD screening diagnostic, NK cell, ALL


 

Granted Patents or Published Applications


 

Related Scientific References

Sullivan EM, Jeha S, Kang G, Cheng C, Rooney B, Holladay M, Bari R, Schell S, Tuggle M, Pui CH, Leung W, “NK Cell Genotype and Phenotype at Diagnosis of Acute Lymphoblastic Leukemia Correlate to Post-induction Residual Disease.” Clin Cancer Res. 2014 Oct 3.


 

Licensing Opportunities

We are currently seeking licensing opportunities in all fields for the development of this technology.

Related Links

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.